Joan Dorca

Risk-Adapted Management for Patients With Clinical Stage I Seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study

Jorge Aparicio, J.R. Germà, Xavier García del Muro et al. · Journal of Clinical Oncology · 2005 · 231 citations

Metformin-induced preferential killing of breast cancer initiating CD44+CD24−/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts

Sílvia Cufí, Bruna Corominas-Faja, Alejandro Vázquez‐Martín et al. · Oncotarget · 2012 · 137 citations · Full text

Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma

Jorge Aparicio, Xavier García del Muro, Pablo Maroto et al. · Annals of Oncology · 2003 · 126 citations · Full text

Clinical Stage, Dual Policy, Surgical Oncology +8

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG)

Jorge Aparicio, Pablo Maroto, Xavier García del Muro et al. · Annals of Oncology · 2014 · 122 citations · Full text

Prognostic Factors, Risk-adapted Studies, Urology +9

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial

Marco Colleoni, Weixiu Luo, Per Karlsson et al. · The Lancet Oncology · 2017 · 120 citations

Breast Oncology, Medicine, Cancer Management +7